Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 8/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886690 | 0.83 | MAPT (0.59) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL3984848 | 0.82 | MAPT (0.67) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL31459864 | 0.82 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL15172955 | 0.82 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL31459976 | 0.82 | MAPT (0.75) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL3982203 | 0.79 | MAPT (0.64) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL31459968 | 0.77 | MAPT (1.00) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL2921771 | 0.77 | MAPT (1.00) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL16521105 | 0.75 | MAPT (0.78) | KMT2AMEN1MAPTSMN1; SMN2TSHR | |
| SCHEMBL16312402 | 0.74 | MAPT (0.57) | KMT2AMEN1MAPTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828197-B1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| EP-1828197-A1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE | Solvay Pharmaceuticals GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063615-A1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | KMT2A 2945/4885MEN1 2028/4885MAPT 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.